Quantum Computing (QUBT) Soars Anew on Bullish Outlook
Quantum Computing Inc. (NASDAQ:QUBT) is one of the .
Quantum Computing jumped by 27.22 percent on Monday to close at $21.22 apiece as investors continued to snap up shares following Nvidia Corp. CEO Jensen Huang's optimistic comments on quantum computers.
In his keynote speech at a conference in Paris recently, Huang said that the application of quantum computers in areas that can solve interesting problems is now within reach.
'This is a really exciting time,' he noted.
Earlier this year, Huang walked back his comment that the practical use of quantum computers is only 15 to 30 years away.
A data analyst pouring over a chart, the intricacies of its lines being revealed.
Last week, Ascendiant Capital Markets reaffirmed its 'buy' recommendation on Quantum Computing Inc.'s (NASDAQ:QUBT) stock, while raising its price target to $22 from $14 previously.
While we acknowledge the potential of QUBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
24 minutes ago
- CNN
Buss family agrees to sell majority stake of Los Angeles Lakers in reported record $10B deal
The Buss family has agreed to sell majority ownership of the Los Angeles Lakers, one of the most storied franchises in all of sports, to Los Angeles Dodgers owner Mark Walter, a source familiar with the agreement told CNN. The valuation of the agreement is approximately $10 billion, representing the most lucrative deal for a professional sports team, according to the Associated Press. ESPN's Shams Charania was first to report the agreed sale. CNN has reached out to the Lakers and Dodgers for comment. Aside from being the chairman and controlling owner of the Dodgers, Walter is the CEO and founder of the holding company TWG Global. The diversified business also holds stakes in the WNBA's Los Angeles Sparks, the Premier League's Chelsea FC and the newly formed Cadillac Formula One team, which is scheduled to make its debut on the grid in 2026, among other sports franchises. On Wednesday, TWG said Walter is entering into an agreement to acquire additional interests in the Lakers. He has owned a minority stake in the franchise since 2021. Basketball Hall of Famer Jerry Buss bought the Lakers in 1979 and oversaw the franchise winning 10 NBA titles. After his death in 2013, his daughter Jeanie Buss took over the role as governor of one of the most successful franchises in sports. Los Angeles added another Larry O'Brien trophy to the collection in 2020, led by LeBron James, the team's 17th NBA championship. Last season, the Lakers finished in third place in the Western Conference with a 50-32 record before being eliminated by the Minnesota Timberwolves in the first round of the NBA playoffs. James still remained one of the better players in the league in his 22nd season, averaging 24.4 points, 7.8 rebounds and 8.2 assists. But the team shocked the world by executing one of the most stunning blockbuster trades in NBA history. Los Angeles acquired NBA superstar Luka Doncic, as well as Maxi Kleber, Markieff Morris from the Dallas Mavericks for Anthony Davis, Max Christie and the Lakers' 2029 first-round draft pick. The NBA's all-time leading scorer reportedly signed a two-year, $104 million maximum contract to return to the Lakers ahead of 2024-2025 season and has a player option to return next season. Team president of basketball operations and general manager Rob Pelinka had previously said James will be keeping an eye on how the roster improves in the offseason. Buss reportedly will continue in her role with the franchise after the sale.
Yahoo
25 minutes ago
- Yahoo
Zebra Technologies Unveils EM45 Android-Based Enterprise Mobile Computer
Zebra Technologies Corporation ZBRA recently introduced EM45 Enterprise Mobile, an Android-based handheld mobile computer. The new solution is part of the broader EM45 series, which also features the EM45 RFID EM45 Enterprise Mobile supports multiple user profiles with separate professional and personal settings. This allows the users to carry a single device to their workplace. The device is equipped with an AI-capable Qualcomm processor. It features one-touch push-to-talk communication and three actionable buttons for quick barcode scanning and emergency alerts. The EM45 Enterprise Mobile supports ZBRA's Workstation Connect, which enables the device to function like a ZBRA solution also comes with a high-capacity battery that is capable of delivering up to 25 hours of uninterrupted power. The company's DNA software suite makes it easy to set up and manage the device. This slim and durable solution is aimed at improving productivity for frontline managers and workers across industries such as retail, healthcare, hospitality, manufacturing and EM45 Enterprise Mobile is designed to handle a wide range of tasks. In retail, it is capable of reading digital wallets, scanning products and accepting payments. This facilitates efficient inventory management for users and reduces product loss. For users across the postal, transportation and logistics sectors, this solution improves route management and provides product delivery proof. Its 50MP camera also captures clear photos and videos and quickly scans barcodes. In the healthcare sector, the device helps medical staff to monitor the location and condition of patients and medical equipment. Zebra Technologies is benefiting from an increase in sales of mobile computing and data capture solutions within the Enterprise Visibility & Mobility segment. Higher sales of RFID products are boosting the Asset Intelligence & Tracking segment's performance. However, the company has been dealing with the adverse impacts of the increased cost of sales. Foreign currency headwinds may affect ZBRA's top currently carries a Zacks Rank #4 (Sell). In the year-to-date period, the stock has lost 25.1%, in line with the industry. Image Source: Zacks Investment Research Some better-ranked companies are discussed below:Life360, Inc. LIF currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks delivered a trailing four-quarter average earnings surprise of 425%. In the past 60 days, the Zacks Consensus Estimate for Life360's 2025 earnings has increased 9.1%. Holdings, Inc. ALRM presently carries a Zacks Rank #2 (Buy). It has a trailing four-quarter average earnings surprise of 15.7%.The Zacks Consensus Estimate for ALRM's 2025 earnings has increased 1.3% in the past 60 Inc. BWEN presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 61.1%.In the past 60 days, the consensus estimate for BWEN's 2025 earnings has increased 14.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Broadwind Energy, Inc. (BWEN) : Free Stock Analysis Report Zebra Technologies Corporation (ZBRA) : Free Stock Analysis Report Holdings, Inc. (ALRM) : Free Stock Analysis Report Life360, Inc. (LIF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
GE HealthCare Technologies Inc. GEHC recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound solution designed to guide non-surgical procedures in urology, colorectal care, and pelvic floor assessments. As demand grows for minimally invasive, office-based procedures, this new system supports real-time interventional guidance across key specialties. Built with direct input from physicians, the bkActiv S Series incorporates advanced transducer technology, intuitive controls, and a versatile, compact design suited for both hospital and outpatient environments. It enables single-handed operation, offers sterile draping options, and provides optimized workflows through adaptive imaging presets. With this launch, GE HealthCare further strengthens its leadership in point-of-care ultrasound, delivering performance and procedural efficiency without compromising on patient comfort or image quality. Shares of the company moved south 2.4% and closed at $71.14 yesterday following the announcement on Monday. In the year-to-date period, GEHC shares have lost 9.1% against the industry's 4.9% growth. The S&P 500 increased 1.2% in the same time frame. However, the launch of the bkActiv S Series strengthens GE HealthCare's long-term growth by deepening its presence in the fast-expanding market for minimally invasive, office-based procedures. As healthcare shifts toward cost-effective, outpatient care, this advanced imaging system positions GEHC to capture demand across urology, colorectal, and pelvic health practices. By expanding its bkPortfolio with solutions tailored for procedural guidance and physician efficiency, GEHC not only broadens its customer base but also builds recurring revenue opportunities through transducer sales, service contracts, and software upgrades. Meanwhile, GEHC currently has a market capitalization of $33.08 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research The bkActiv S Series is designed to empower clinicians with precise ultrasound guidance, delivering clear visualization of anatomical structures to support real-time decision-making during non-surgical procedures. It offers exceptional imaging quality alongside a modern, touch-based interface and includes Prostate Volume Assist, an AI-powered feature that automates prostate measurements, streamlining workflows and improving consistency. The system also enhances procedural confidence in urology and pelvic health by enabling quick image capture and optimized visualization. The interface includes GE HealthCare's TruSense technology and customizable layout options, allowing users to tailor the system to their preferences for efficiency and ease of use. Smart Button technology built into the transducers provides one-handed control, offering clinicians the ability to access multiple functions directly from the probe. High-resolution image capture is supported by advanced digital tools that enhance contrast and detail, while the Image Compare mode allows clinicians to view stored and live images side by side for real-time measurement and comparison. The system also integrates PRISM Technology, including the TruFocus algorithm for automatic image optimization, which improves detail clarity and supports consistent imaging quality. Adaptive Noise Suppression helps reduce background interference and enhances deep-tissue visualization by dynamically adjusting gain levels during scanning. Combined, these features make the bkActiv S Series well-suited for a variety of procedures, including prostate diagnostics, biopsies, and treatment guidance, in both hospital and office-based settings. In June, GE HealthCare launched MIM Encore, an integrated imaging software suite that enhances workflows and diagnostic precision across oncology, cardiology, and neurology. In May, it introduced CleaRecon DL, a deep-learning CBCT tool that improves image clarity in interventional procedures and received both FDA and CE approvals. Earlier in March, GEHC unveiled Freelium, a next-gen MRI platform using less than 1% helium, aimed at expanding sustainable imaging access. These developments reflect GEHC's ongoing push to combine advanced hardware with AI-powered imaging innovation. GEHC carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
